Geneos Wealth Management Inc. Purchases 7,777 Shares of Stryker Corporation $SYK

Geneos Wealth Management Inc. grew its position in shares of Stryker Corporation (NYSE:SYK) by 50.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,132 shares of the medical technology company’s stock after purchasing an additional 7,777 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Stryker were worth $9,152,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. acquired a new stake in Stryker in the second quarter valued at $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the second quarter worth approximately $28,000. Sachetta LLC boosted its holdings in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares during the last quarter. Kilter Group LLC acquired a new stake in Stryker during the 2nd quarter valued at approximately $29,000. Finally, Howard Hughes Medical Institute bought a new position in Stryker during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $353.99 on Friday. The firm has a market capitalization of $135.37 billion, a P/E ratio of 46.52, a P/E/G ratio of 2.51 and a beta of 0.89. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The stock has a 50 day moving average price of $366.81 and a two-hundred day moving average price of $378.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. Stryker’s payout ratio is 44.15%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Barclays increased their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Finally, BTIG Research reiterated a “buy” rating and issued a $410.00 price objective on shares of Stryker in a research note on Friday, November 14th. Twelve analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $431.83.

Insider Transactions at Stryker

In related news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This trade represents a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last 90 days. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.